Vanguard Capital Management
ABUS icon

Vanguard Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Vanguard Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.7M Buy
7,010,679
+321,768
+5% +$1.41M ﹤0.01% 2148
2026
Q1 		$30.1M Buy
+6,688,911
New +$29.2M ﹤0.01% 2123

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management's ABUS Position: Q2 2026 in Review

Vanguard Capital Management increased its Arbutus Biopharma (ABUS) stake by 4.8% in Q2 2026, buying an estimated $1.41M and bringing the position to 7,010,679 shares worth $33.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2148.

Vanguard Capital Management first reported a position in ABUS in Q1 2026 and has held it in 2 quarters since. 175 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Vanguard Capital Management held 7,010,679 shares of Arbutus Biopharma worth $33.7M as of Q2 2026.
  • Vanguard Capital Management bought 321,768 Arbutus Biopharma shares in Q2 2026, an estimated $1.41M.
  • Arbutus Biopharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2148 holding.
  • Vanguard Capital Management first reported a position in Arbutus Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 175 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.